Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other p
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. (OTCQB: ... 400 million people worldwide are living with diabetes, with  ... by 2030.  The global market for diabetes treatments is ... 330,000 people worldwide died from pancreatic cancer.  Pancreatic cancer ... to cancer in the United States ...
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Twelve-Week Maintenance DosingBEERSE, Belgium, Jan. 22 ... a new class of biologics, has been approved by ... approved indication of ustekinumab is for the treatment of ... to respond to, or who have a contraindication to, ...
... Cell Innovations, Inc., (SCLL.PK) announced today that it has filed a new ... cells. , ... Houston, TX (PRWEB) January 22, 2009 -- Stem Cell ... application for the production of pluripotent stem cells from primordial germ cells. ...
... for testing the quality of a sperm before it ... conception. , Researchers at the University of Edinburgh, funded ... have created a way of chemically ,fingerprinting, individual sperm ... consider whether the sperm is healthy enough to be ...
Cached Biology Technology:New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 2New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 3New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 4Stem Cell Innovations, Inc., Files New Patent Application 2Stem Cell Innovations, Inc., Files New Patent Application 3New sperm shaker to improve IVF success 2
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... hormone-like compounds linked to the consumption of soy-based foods ... brain, resulting in early-onset puberty and symptoms of advanced ... by researchers at North Carolina State University. The study ... cause reproductive health problems, as well as in providing ...
... a drug to achieve normal levels of blood ... high insulin levels. If this approach succeeds in ... children with congenital hyperinsulinism, a rare but potentially ... dangerously high. "There is currently no effective ...
... that measure pressure within the eye and dispense ... new material developed by biomedical engineers at UC ... engineering, and postdoctoral researcher Hailin Cong started with ... method for placing powdered silver on the PDMS ...
Cached Biology News:New study shows compounds from soy affect brain and reproductive development 2Treatment corrects severe insulin imbalance in animal studies 2Treatment corrects severe insulin imbalance in animal studies 3
Recombinant Mouse IL-23, CF...
Rabbit Serum New Zealand or California Origin...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
... Synthesis , Containing one Phospho-Amino Acid , ... customer conjugation of peptide to KLH protein , Rabbits ... , Pre-immune bleed x1 /each , ... bleed (app. 5 ml) x1 /each , ...
Biology Products: